For nearly 50 years, immunotherapy has been used in patients with bladder cancer in the
form of Mycobacterium bovis Bacillus Calmette-Guerin (BCG), which is still the first-line …

Non-muscle invasive bladder cancer (NMIBC) accounts for~ 70–75% of total bladder cancer
tumors and requires effective early intervention to avert progression. The cornerstone of high …

Intravesical instillation of Bacillus Calmette-Guérin has been used as an immunotherapy to
treat superficial bladder cancer for almost half a century. In recent years, the approval of …

Background Tumor recurrence and progression in non-muscle invasive bladder cancer
(NMIBC), therapy failure, and severe side effects in muscle invasive bladder cancer (MIBC) …

Device-assisted intravesical chemotherapy treatment for nonm... : Current Opinion in
Urology Device-assisted intravesical chemotherapy treatment for nonmuscle invasive …

Effective bladder-preserving therapeutic options are needed for patients with bacillus
Calmette-Guérin unresponsive non–muscle-invasive bladder cancer. Nadofaragene …

Disruptions in normal development and the emergence of health conditions often result from
the malfunction of vital genes in the human body. Decades of scientific research have …

Bladder cancer is a heterogeneous disease. Treatment decisions are mostly decided based
on disease stage (non-muscle invasive or muscle invasive). Patients with muscle-invasive …

Traditional cisplatin-based chemotherapy has long been the mainstay treatment for
advanced urothelial carcinoma (UC), but the emergence of immune checkpoint inhibitors …

Background The KEYNOTE-057 trial evaluated activity and safety of pembrolizumab in
patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer who were …